While 2017 saw the entrance of the first two drugs for tardive dyskinesia, the percentage of TD patients who are actually diagnosed remains in the single digits. Neurocrine is looking to change that ...
Neurocrine Biosciences has successfully diversified beyond Ingrezza, with Crenessity's rapid adoption validating its multi-franchise commercial strategy. NBIX's late-stage neuropsychiatry pipeline, ...
Austedo (deutetrabenazine) and Ingrezza (valbenazine) are prescription drugs used to treat tardive dyskinesia and chorea associated with Huntington’s disease. Austedo and Ingrezza are not available as ...
SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the ...
The FDA approved Neurocrine Biosciences Inc's (NASDAQ:NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD). Ingrezza is the only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results